Skip to Main Content

Immunotherapies have transformed cancer care by enlisting the body’s own immune system to fight tumors that have evaded or hijacked normal defenses. But while checkpoint inhibitor drugs and bespoke CAR-T treatments have gained significant ground in recent years, another type of immunotherapy — cancer vaccines — have seen far less success.

New research published this week in Nature Cancer, however, suggests combining a cancer vaccine with adjuvant molecules might boost effectiveness in preventing melanoma recurrence, potentially opening the door to future combinations with other immunotherapies to vanquish cancers. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!